IL43992A - Racemic 13beta-ethyl-3-methoxy-8,14-seco-gona-1,3,5(10),8-tetraene-17beta-ol-14-one and a process for the preparation thereof - Google Patents

Racemic 13beta-ethyl-3-methoxy-8,14-seco-gona-1,3,5(10),8-tetraene-17beta-ol-14-one and a process for the preparation thereof

Info

Publication number
IL43992A
IL43992A IL43992A IL4399274A IL43992A IL 43992 A IL43992 A IL 43992A IL 43992 A IL43992 A IL 43992A IL 4399274 A IL4399274 A IL 4399274A IL 43992 A IL43992 A IL 43992A
Authority
IL
Israel
Prior art keywords
ethyl
gona
methoxy
tetraene
seco
Prior art date
Application number
IL43992A
Other versions
IL43992A0 (en
Original Assignee
Richter Gedeon Vegyeszet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Vegyeszet filed Critical Richter Gedeon Vegyeszet
Publication of IL43992A0 publication Critical patent/IL43992A0/en
Publication of IL43992A publication Critical patent/IL43992A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Description

Racemic 13M-ethyl-3methoxy-8 ,14-seco-gona-l , 3 , 5 (10$ ,8-tetraene- 17β-ο1-14-οηβ and a process for the preparation thereof Richter Gedeon Vegyeszeti Gyar R.T.
This invention relates to racemic 13B-et yl-3- methoxy-8 , 14-seco-gona- ,3,5(10),8-tetraene-17B~ol-1 -one , a novel compound, as well as to a process for the preparation thereof. This compound can be utilized with great advantages in the total synthesis of certain gonane derivatives.
It is known that one of the oxo groups of 13-ethyl-3-methoxy-8, -seco-gona- , 3, 5(10) , 9-tetraene , 14, 17-dione can be selectively reduced with sodium borohydride to form a secondary alcohol group (see U.S. Patent Specification No. j¾ 54-9*673). According to the same reference (see lines 39 to 5 of column 3 and lines 1 to 23 of column 4), in this reaction racemic 3B-ethyl-3-methoxy-8, 4-seco-gona-1}3»5( O),9-tetraene-17 -ol-1 -one is formed exclusively.
This invention is based on the recognition that when reducing l3-ethyl-3-methoxy-8, 4-seco-gona-1 , 3, 5(10) , 9-tetraene-^, 17-dione with sodium borohydride of an amount necessary for the reduction of one of the oxo groups, in the presence of an alkali metal hydroxide and/or alcoholate, a diastereomeric mixture containing racemic 13B-ethyl-3-methoxy-8, -seeo-gona-1 , 3> 5(10) , 9-tetraene-17B-ol-14~one as main product is formed, and if this crude diastereomeric mixture is treated with an organic acid containing 5 to 15 % of water, then the racemic 13fi-ethyl-3-niethoxy-8, 14-seco-gona-1,3,5( O),9-tetraene-17 -ol-14-one by-product quantita^ tively converts into the known racemic 13fl-ethyl-3-methoxy-8,1 -seco-9§ ,1 « -oxido-gona-1,3»5(IO)-triene-17-one, while the main product, that is, the 17B-hydroxy-14-one compound, converts into the novel racemic 3B-ethyl-3-methoxy-8, 14-seco-gona-1,3,5(lO),8-tetraene-17B-ol-1 -one. The compounds obtained in this way greatly differ from each other with respect to their polarities and thus they can be easily separated from each other. Such type of the 9 > 8(9) isomerisation of a double bond was hitherto unknown in the seco-steroid series. e have found further that when acetylating racemic 3B-ethyl-3-methoxy-8, 14-seco-gona-1 , 3, 10) f8-tetraene-17B-ol-14-one and treating, the reaction mixture with an acid, the known racemic 13B-ethyl-3-methoxy-gona-1 , 3, 5(10) ,8, 14-pentaene-17B-ol-acetate can be obtained with an excellent yield. This latter compound is an important starting substance for the preparation of 13B-ethyl-gonane derivatives.
It was already known that when reducing 13-ethyl-3-methoxy-8, 4-seco-gona- , 3 » 5(10) j 9-tetraene-14, 17-dione with lithium tri-tert.butoxy aluminium hydride, besides the main product, i.e., racemic 3£-etyhl-3-methoxy-8, 14-seco-gona-1, 3 > 5( 0) , 9-tetraene-17<<-ol-14-one, also a diastereomeric by-product, i.e., racemic 13B-ethyl-3-methoxy-8,14-seco-gona- , 3» 5( 10) , 9-tetraBne-17B-ol-l4-one is formed (J. Med. Ohem. 1j?, 360 /1972/) . According to the practice, however, neither this mixture, nor the diastereomeric mixture of racemic 3fl-ethyl-3-methoxy-gona-1 * 3» (10),8,14-pentaene-17« -ol-acetate and of the corrsponding 17B-compound, prepared by acetylating the former mixture and subjecting the products of acetylation to ring closure, can be used for carrying out further stereospecific reactions, and the diastereomers of steroid skeleton can be separated from each other only with great difficulties (J. Med. Chem. 360 / 72/) .
The racemic 13B-ethyl-3-methoxy-8, 14-seco-gona- 1 » 3 , 5(10),8-tetraene-17B-Ql-1 -oiie is prepared according to the invention as follows: one of the oxo groups of 13-ethyl» 3-methoxy-8, 4~seco-gona- , 3, 5(10) , 9-tetraene-1 , 17-dione is deduced with sodium borohydride in the presence of an alkali metal hydroxide and/or alcoholate, the obtained liastereomeric mixture, consisting mainly of racemic 13B~ 3thyl-3-methoxy-8,1 -seco-gona-1»3,5( O),9-tetraene-17B-ol~~ 14~one, is reacted with an organic acid, preferably with a C^_6 aliphatic carboxylic acid, and the obtained 13B-ethyl-3-methoxy-8, 1 -seco-gona-1 , 3, 5(10) ,8-tetraene- 7B-ol-1 -one is, separated from the reaction mixture.
The above reactions are preferably carried out by reducing 3-ethyl-3-methoxy-8, 1 -seco-gona-1 , 3, 5(10) , 9-tetraene-1 , 17-dione, dissolved in 0.1 n methanolic sodium hydroxide, with sodium borohydride, wherein the latter reactant is used in an amount sufficient to reduce only one of the oxo groups. The reaction is carried out preferably at a temperature between +20° and +60°; within this range the room temperature is the most preferred. The diastereo-meric mixture of the 1 -S-hydroxy-1 -one and 17«C -hydroxy-1 -one compounds, obtained after processing the above reaction mixture, is treated at room temperature with acetic acid containing 5 to 15 of water, thereafter the reaction, mixture is evaporated to dryness. The residue is subjected to column chromatography, to yield the syrup-like racemic 13fi-ethyl-3-methoxy-8,1 -seco-gona-1 ,3, (10) ,8-tetraene-17£-ol-1 -one.
The main advantages of the process according to the invention are as follows; a) Using this modified sodium borohydride reduction of 13-ethyl-3-methoxy-8, 1 -seco-gona-l , , (10) ,9-tetraene- 14,17-dione, the 3B-ethyl-3-methoxy-8, 14-seco-gona-1 , 3, 5( 19. tetraene-17B-ol-14-one is obtained as main product, instead of the 17 eC -compound. b) When treating the diastereomeric mixture of the t 17B- and 17 eC -hydroxy-14-one compounds with an organic acid, both of the isomers convert into the different corresponding products which, due to their highly different polarities, can readily be separated from each other. In this latter reaction the 17B-hydroxy-14-one compound converts into a new derivative, that is, into racemic 13B-e l-3-methoxy- 8,1 -seco-gona-1,3,5(10),8-tetraene-17fl-ol-14-one- which is a valuable intermediate for the total synthesis of 13B-ethyl- gonane derivatives, since it can be converted, even in crude state, into racemic 13B-ethyl-3-methoxy-gona-1,3,5(10) ,8,14-5 pentaene-17B-ol-acetate with excellent yields.
The invention is. further illustrated by the aid of the following, non-limiting Example.
Example Step (a) ; Preparation of racemic 13B-ethyl-3-methoxy- 8, 4-seco-gona- , 3, 5(10) ,8-tetraene-17B-ol-14-one 50 g. of 13-ethyl-3-methoxy-8, 4-seco-gona-1,3,5(10),9- tetraene-14,17-dione (prepared according to the method described in J. Org. Ohem. j£, 3126 /1968/) are dissolved in 2.5 litres, of 0.1 n methanolic sodium hydroxide, and 2.5 g. of sodium borohydride are added to the solution at 20 °C.
After 0.5 hours of stirring the mixture is neutralized with glacial acetic acid and evaporated to dryness. The dry residue is dissolved in a mixture of water and ethyl acetate, then the organic phase is separated and evaporated to dry- ness. The thus-obtained residue (50 g.), consisting of racemic 3B-ethyl-3-methoxy-8 , 14~seco-gona- , 3 , 5(10) ,9-tetraene-17B-ol-14-one and racemic 13B-ethyl-3-methoxy-8, 14-seco-gona-1, 3 , 5(10) , 9-tetraene-17<< -ol-14-one, is dissolved in 2.5 litres of a 9:1 mixture of acetic acid and water, and the obtained solution is left to stand at room temperature for 72 hours* Thereafter the reaction mixture is evaporated to dryness at 3 °0, under reduced pressure. The obtained oily residue ( 9 g.) is dissolved in benzene and subjected to chromatography on a silica gel column. The elution is started with benzene containing 2.5 of ethyl acetate.
The obtained effluent is evaporated to yield the racemic 13B-ethyl-3-methoxy-8,14-seco-9'l) ,14«C -oxido-gona- * 3j (10)-triene-17-one by-product. The elution is continued with benzene containing" 5 # of ethyl acetate, and the effluent is evaporated. In this way 30 g. of a syrup-like residue is obtained, consisting of crude racemic 13fi-ethyl<~ 3-methoxy-8,14-seco-gona- , 3, 5(10) , 8-tetraene-17B-ol-14-one .
A small portion of this product is purified by chromatography for analytical purposes. As adsorbent, a 1:1 mixture of Kieselgel ^2^-366 (Merck) and Kieseleel G (Merck) is used, and development is carried out with a 98:1:1 mixture of chloroform, acetone and methanol, The spot appearing at Hf - 0.31 is eluted, and the eluate is evaporated. Syrup-like, pure, uniform 3B-ethyl-3-methoxy-8,14-seco-gona-1, 3, 5(10) , 8-tetraene-17B-ol-14-one is obtained, λ e hanol 270 ( . - 10, 500) max, Λ IS (film): > - 3440 (OH), 1720 (G-0), 1602, 1565, W6 cm" (aromatic 0*0).
NMR: cT = 0.90 (t, CH3/CH2/); 3.77 (s, CH^) $ 4.24 (t, 0-17 H, J - 5.5 Hz); 5-7 (t, C-8 H, J = 4 Hz); 6.6 to 6.8 (m,, 0-4 H and 0-2 H, Jmeta - 2.5 Hz, Jortho . 9-5v Hz); 7.15 (d, 0-1 H, J = 9.5 Hz) ppm.
Step (b): Preparation of racemic 13B-ethyl-3-methoxy»-gona- ,3, ( 10) , 8 , 14-pentaene-17B-ol-acetate 3 g. of crude racemic 3B-ethyl-3-methoxy-8, 14-seco-gonarl ,3» ( 10) , 8-tetraene-17B-ol-14-one (prepared as described in Step /a/) are boiled for 12 hours in a mixture of 270 ml. of abs. benzene*, 35 ml. of pyridine and 30 ml. of acetic anhydride. The reaction mixture is extracted with 3x100 ml, of 2.5 % aqueous hydrochloric acid, then with 2x100 ml. of 5 ^ aqueous sodium- hydrocarbonate solution, and finally with 100 ml.. of water. The benzene solution is dried by distilling off 80 ml. of benzene, thereafter 1 .4 g. of p-toluenesulfonic acid are added to the residue, and the mixture is boiled for 5 hours under a water separator. The reaction mixture is cooled, washed until neutral with 190 ml. of 5 % aqueous sodium hydrocarbonate solution and then with 100 ml. of water, dried over sodium sulfate, and evaporated to dryness. The oily residue ( 29.5 g.) is treated with methanol to form 22.0 g. of a uniform, crystalline product.
The obtained racemic 1^B-ethyl-3-methoxy-gona-1 , 3, 5(10) , 8 , 14- , „ , nn O, 1 methanol pentaene-17B-ol-acetate melts at 87 to 89 C? λ maXe = 314T¾n ( £ = 28, 950) .

Claims (7)

1. Racemic 13p-ethyl-3-methoxy-8, 14-eeco-gona-l, 3, 5(10) ,8- tetraene-17p-ol-14-one .
2. A process for the preparation of racemic 13p-ethyl-3-methoxy- 8,14-seco-gona-l,3,5(10) , 8-tetraene-17p-ol-14-one , in which one of the oxo groups of 13-ethyl-3-methoxy-8, 14-seco-gona- l,3,5(l0),9-tetraene-14,17-dione is reduced with sodium borohydride in the presence of an alkali metal hydroxide and/or alcoholate, the obtained diastereomeric mixture, containing racemic 13p-ethyl-3-methoxy-8,14-seco-gona--l,3, 5 (10) ,9-tetraene-17p-ol-14-one as main component, is reacted with an organic acid, and the obtained racemic 13p-ethyl- 3-methoxy-8 , 14-seco-gona-1 , 3 , 5 ( 10) , 8-tetraene-17f>-ol-14- one is separated from the reaction mixture.
3. A process as claimed in claim 2, in which the organic acid is a aliphatic carboxylic acid.
4. A process as claimed in claim 3, in which the aliphatic . carboxylic acid is acetic acid.
5. Racemic 13p-ethyl-3-methoxy-8,14-seco-gona-l,3,5(10) ,8- tetraene-17p-ol-14-one, whenever prepared by a process as claimed in claim 2, or by an obvious chemical equivalent thereof.
6. A process as claimed in any of claims 2 to 4, for preparing racemic 13p-ethyl-3-methoxy-8, 14-seco-gona-l,3, 5(10) ,8- tetraene-17p-ol-14-one .
7. A process for the preparation of racemic 13p-ethyl-3-methoxy- 8 , 14-seco-gona-l ,3,5(10),8-tetraene-17p-ol-14-one , substantially as hereinbefore described with reference to the Example.
IL43992A 1973-01-31 1974-01-10 Racemic 13beta-ethyl-3-methoxy-8,14-seco-gona-1,3,5(10),8-tetraene-17beta-ol-14-one and a process for the preparation thereof IL43992A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HUGO1230A HU170147B (en) 1973-01-31 1973-01-31

Publications (2)

Publication Number Publication Date
IL43992A0 IL43992A0 (en) 1974-05-16
IL43992A true IL43992A (en) 1977-07-31

Family

ID=10996741

Family Applications (1)

Application Number Title Priority Date Filing Date
IL43992A IL43992A (en) 1973-01-31 1974-01-10 Racemic 13beta-ethyl-3-methoxy-8,14-seco-gona-1,3,5(10),8-tetraene-17beta-ol-14-one and a process for the preparation thereof

Country Status (18)

Country Link
JP (1) JPS5641610B2 (en)
AT (1) AT346505B (en)
BE (1) BE810381A (en)
BG (1) BG23904A3 (en)
CS (1) CS165309B2 (en)
DE (1) DE2403985C2 (en)
DK (1) DK138314B (en)
ES (1) ES422607A1 (en)
FR (1) FR2216275B1 (en)
GB (1) GB1420892A (en)
HU (1) HU170147B (en)
IL (1) IL43992A (en)
IT (1) IT1043869B (en)
NL (1) NL7401256A (en)
RO (1) RO67880A (en)
SE (1) SE400977B (en)
SU (1) SU561515A3 (en)
YU (1) YU35750B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE541390C2 (en) * 2017-12-20 2019-09-10 Scania Cv Ab System and Method for Controlling a Motor Vehicle to Drive Autonomously
SE541389C2 (en) * 2017-12-20 2019-09-10 Scania Cv Ab System and Method for Controlling a Motor Vehicle to Drive Autonomously

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3549673A (en) * 1967-03-09 1970-12-22 Takeda Chemical Industries Ltd Total synthesis of 13beta-substituted gonapolyen-17alpha-ols

Also Published As

Publication number Publication date
NL7401256A (en) 1974-08-02
JPS5641610B2 (en) 1981-09-29
YU10374A (en) 1980-10-31
GB1420892A (en) 1976-01-14
ES422607A1 (en) 1977-04-16
IL43992A0 (en) 1974-05-16
DE2403985C2 (en) 1984-03-01
AT346505B (en) 1978-11-10
DK138314B (en) 1978-08-14
CS165309B2 (en) 1975-12-22
FR2216275A1 (en) 1974-08-30
DE2403985A1 (en) 1974-08-08
JPS5046653A (en) 1975-04-25
BG23904A3 (en) 1977-11-10
IT1043869B (en) 1980-02-29
FR2216275B1 (en) 1977-09-23
SU561515A3 (en) 1977-06-05
DK138314C (en) 1979-02-05
BE810381A (en) 1974-05-16
ATA38374A (en) 1978-03-15
RO67880A (en) 1980-12-30
SE400977B (en) 1978-04-17
YU35750B (en) 1981-06-30
HU170147B (en) 1977-04-28

Similar Documents

Publication Publication Date Title
Heather et al. Synthesis of the witchweed seed germination stimulant (+)-strigol
GB1599863A (en) Pharmaceutical compositions for use in the inhibition of the biosynthesis of mevalonic acid
IE50815B1 (en) 25-hydroxy-26,26,26,27,27,27-hexafluorocholecalciferol
US3928397A (en) New 5-cholestene derivatives and preparation thereof
EP0071153B1 (en) Androstane derivatives, process for their preparation and pharmaceutical compositions containing them
Bohlin et al. Sterols in marine invertebrates. 33. Structure of five new 3. beta.-(hydroxymethyl)-a-nor steranes: Indirect evidence for transformation of dietary precursors in sponges
Heltzel et al. Synthesis and structure-activity relationships of cytotoxic 7-hydroxy sterols
US3803184A (en) Method for preparing desmosterol
EP0015122B1 (en) New 25-hydroxy-24-oxocholestane derivatives and preparation thereof
IE49532B1 (en) 24,24-difluoro-25-hydroxycholecalciferol
IL43992A (en) Racemic 13beta-ethyl-3-methoxy-8,14-seco-gona-1,3,5(10),8-tetraene-17beta-ol-14-one and a process for the preparation thereof
KR970005317B1 (en) Derivatives of 19-norprogesterone, methods of producing them and pharmaceutical compositions incorporating them
Peterson et al. Microbiological Transformation of Steroids. XIII. Oxygenation of 16α, 17α-Oxidoprogesterone to 11α-Hydroxy-16α, 17α-oxidoprogesterone by Rhizopus Nigricans Ehrb.(ATCC 6227b)
EHRENSTEIN et al. INVESTIGATIONS ON STEROIDS. XIII. TRANSFORMATION OF STROPHANTHIDIN INTO COMPOUNDS STRUCTURALLY RELATED TO STEROID HORMONES1
US4360472A (en) Trihydroxyvitamin D3 compounds
Gardner et al. Total synthesis of some (+-)-18-methyl-9. beta., 10. alpha.-androstanes and (+-)-18-methyl-9. beta., 10. alpha.-D-homoandrostanes
Milas The synthesis of vitamin A and related products
EP0000073A1 (en) 24-Dehydrovitamin D3 derivatives and preparation thereof and compositions containing same
Anisuzzaman et al. Improved synthesis of acylated 3-amino-3-deoxy-D-ribofuranose
Barnes et al. The synthesis of desoxyequilenin. The stereochemistry of the C/D ring junction of some steroid intermediates
Johnson et al. Cationic Cyclizations Involving Olefnic Bonds. III. 1 On the Mechanism of Formation of trans-Fused Rings
US3984476A (en) D-homo-19-norsteroids
Zalkow et al. Synthesis of intermedeol and related sesquiterpenoid studies
Pelletier et al. Structures of cuauchichicine, garryfoline, lindheimerine, and ovatine. Chemical correlation of cuauchichicine with (-)-". beta."-dihydrokaurene
US4078059A (en) Novel 2,2-dimethyl steroids